BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12524139)

  • 1. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
    Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
    Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
    Di Marzo V; Berrendero F; Bisogno T; González S; Cavaliere P; Romero J; Cebeira M; Ramos JA; Fernández-Ruiz JJ
    J Neurochem; 2000 Apr; 74(4):1627-35. PubMed ID: 10737621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
    Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.
    Breivogel CS; Childers SR; Deadwyler SA; Hampson RE; Vogt LJ; Sim-Selley LJ
    J Neurochem; 1999 Dec; 73(6):2447-59. PubMed ID: 10582605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
    Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
    J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
    Oviedo A; Glowa J; Herkenham M
    Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
    Sim LJ; Hampson RE; Deadwyler SA; Childers SR
    J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA; Járai Z; Bátkai S; Kunos G
    Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM; Martin BR
    Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata.
    Szabo B; Wallmichrath I; Mathonia P; Pfreundtner C
    Neuroscience; 2000; 97(1):89-97. PubMed ID: 10771342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
    Rubino T; Viganò D; Massi P; Parolaro D
    J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
    Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
    Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.
    Lake KD; Compton DR; Varga K; Martin BR; Kunos G
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1030-7. PubMed ID: 9190833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
    Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
    Breivogel CS; Griffin G; Di Marzo V; Martin BR
    Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity.
    Wiley JL; Jefferson RG; Griffin G; Liddle J; Yu S; Huffman JW; Martin BR
    Pharmacology; 2002 Oct; 66(2):89-99. PubMed ID: 12207116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.